3M 2007 Annual Report Download - page 20

Download and view the complete annual report

Please find page 20 of the 2007 3M annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 100

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100

14
In 2007, the Company modified elements of its long-term incentive compensation programs. With the May 2007
Management Stock Ownership Program (MSOP) Annual Grant, the Company reduced the number of traditional stock
options granted by reducing the number of employees eligible to receive annual grants and by shifting a portion of the
annual grant away from traditional stock options primarily to restricted stock units. These changes will reduce the
annual dilution impact from approximately 1.5% of total outstanding common stock to approximately 1%. However,
associated with the reduction in the number of eligible employees, the Company provided a one-time “buyout” grant of
restricted stock units to the impacted employees, which resulted in increased stock-based compensation expense in
2007. Stock-based compensation expense totaled $0.18 per diluted share in 2007, compared with $0.17 per diluted
share in 2006. The Company’s MSOP, including restricted stock units, is discussed further in Note 15.
The preceding forward-looking statements involve risks and uncertainties that could cause results to differ materially
from those projected (refer to the forward-looking statements section in Item 7 and the risk factors provided in Item 1A
for discussion of these risks and uncertainties).
(Note A). In 2007, gains on sale of businesses and real estate, net of restructuring and other items, increased
operating income by $681 million and net income by $448 million, or $0.62 per diluted share. 2007 included net
benefits from gains related to the sale of businesses ($849 million pre-tax, $550 million after-tax) and a gain on sale of
real estate ($52 million pre-tax, $37 million after-tax), which were partially offset by increases in environmental liabilities
($134 million pre-tax, $83 million after-tax), restructuring actions ($41 million pre-tax, $27 million after-tax), and other exit
activities ($45 million pre-tax, $29 million after-tax). These items, except the gain on sale of real estate, are discussed in
more detail in Note 2 (Acquisitions and Divestitures), Note 4 (Restructuring Actions and Other Exit Activities) and Note 13
(Commitments and Contingencies). Gains on sale of businesses include the second-quarter 2007 sale of 3M’s Opticom
Priority Control Systems and Canoga Traffic Detection businesses, and the first-quarter 2007 sale of the global
branded pharmaceuticals business in Europe. Concerning the real estate sale, 3M sold its current lab facility located in
Suwon, Korea and is currently building a new state-of-the-art customer-oriented R&D facility closer to Seoul and many
of 3M’s major customers.
In 2006, gains of sale of businesses, net of restructuring and other items, increased operating income by $523 million
and net income by $438 million, or $0.57 per diluted share. 2006 included net benefits from gains related to the sale of
certain portions of 3M’s branded pharmaceuticals business ($1.074 billion pre-tax, $674 million after-tax) and
favorable income tax adjustments ($149 million), which were partially offset by restructuring actions ($403 million pre-tax,
$257 million after-tax), acquired in-process research and development expenses ($95 million pre-tax and after-tax),
settlement costs of a previously disclosed antitrust class action ($40 million pre-tax, $25 million after-tax), and
environmental obligations related to the pharmaceuticals business ($13 million pre-tax, $8 million after-tax). These items,
except the settlement costs and environmental obligations, are discussed in more detail in Note 2 (Acquisitions and
Divestitures), Note 4 (Restructuring Actions and Other Exit Activities), Note 8 (Income Taxes) and Note 13 (Commitments
and Contingencies). Concerning settlement costs, the Company recorded $40 million in 2006 with respect to a settlement
in principle related to the antitrust class action brought on behalf of direct purchasers who did not purchase private label
tape. Concerning environmental obligations, the Company increased its reserves by $13 million during 2006 for
estimated environmental remediation costs at a European pharmaceutical plant.